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Myocilin, expressed in the trabecular meshwork cells of the human eye, has been 
linked to inherited primary open-angle glaucoma (POAG), an illness characterized by 
increased intraocular pressure and irreversible vision loss(1)(1)(1)(1)(1)(1)(1)(1)(1). 
Disease-causing point mutation variants of myocilin, over 90% of which are found in its 
olfactomedin (OLF) domain, cause its aggregation in the endoplasmic reticulum (ER) of 
trabecular meshwork cells, as shown by cellular secretion studies. This accumulation of 
protein triggers unfolded protein response within these cells, which ultimately leads to 
apoptosis. The cellular debris has been suggested to compromise the trabecular 
meshwork, lead to poor regulation of aqueous humor flow and increase in intraocular 
pressure, and finally, to an early glaucoma diagnosis. Since its discovery in 1997, 
biophysical characterization of myocilin has been hindered by poor expression and low 
yields. I overcame this severe limitation in the study of myocilin by fusing the full length 
and OLF domains independently to maltose binding protein (MBP) via a short linker.  
Using the MBP-OLF construct, I used site-directed mutagenesis to generate a total of 21 
reported disease-causing variants, which were likewise expressed and purified.  
The stability of wild-type and mutant OLFs were assessed in order to gain insight 
into the biophysical roles of particular mutations in glaucoma. I adapted differential 
scanning fluorimetry, a method to follow the unfolding of a protein using a fluorescence 
of a dye sensitive to hydrophobic regions of a protein that become exposed during 
denaturation, for facile stability measurements of OLFs without the removal of MBP. 
Initially, the melting temperatures for wild-type OLF and four variants (D380A, I477S, 
I477N and K423E) were determined, ranging in phenotype from mild to severe, 
ix 
 
respectively. A correlation between the extent of glaucoma severity and thermal stability 
of the particular mutant was observed during these initial trials, and trends were solidified 
by the addition of the melting temperatures of 19 more other disease-causing variants. 
Next, I investigated the possibility of restoring mutant OLF stability to wild type 
levels with small molecules.  This experiment was motivated by a therapeutic approach 
for myocilin glaucoma that aims to restore mutant myocilin stability, and thus enable its 
secretion, via escaping detection by endoplasmic reticulum quality control proteins. The 
net effect of such a therapy would be to alleviate stress of the cell and keep the trabecular 
meshwork intact. As proof of principle for this therapeutic direction, changes in the 
stability of OLF mutants were measured in the presence of osmolytes, compounds known 
to stabilize proteins primarily by their effect on the protein backbone. Of the seven 
osmolytes tested, sarcosine and trimethylamine-N-oxide restored the melting temperature 
of the mutant OLF to approximately that of wild-type. 
Taken together with previous qualitative assays examining the extent of solubility 
of mutant myocilins in Triton X-100, and temperature-sensitive secretion from 
mammalian cells, combined with trends observed in age of diagnosis of glaucoma, my 
work shows a strong correlation between the biophysical properties of the mutant and 
severity of glaucoma. Specifically, variants with low melting temperatures are associated 
with more severe glaucoma phenotypes, are generally insoluble in Triton X-100, and are 
neither secreted from cells at 37 °C nor at 30 °C. Conversely, three mutants (G246R, 
A427T, and A445V) have similar melting temperatures, and comparable circular 
dichroism spectra to wild-type, suggesting an error in their assignment as pathogenic. 
Lastly, three reported variants caused by single nucleotide polymorphisms (E352Q, 
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E396D, and K398R) displayed melting temperatures above wild-type OLF, confirming 
that these are also benign mutations.  
Overall, my thesis describes a quantitative correlation between glaucoma 
phenotype and reported-disease causing mutations. This work offers a quantitative and 
facile evaluation method to distinguish disease-causing mutants from benign mutants for 
glaucoma. This approach is likely to be further applicable to other genetic diseases 




PROTEIN EXPRESSIONAND PURIFCATION 
Introduction 
 Glaucoma, the leading cause of blindness, currently affects about 70 million 
people worldwide (2) This illness is characterized by irreversible blindness and an 
increased intraocular pressure (1). The control of the flow of aqueous humor, found 
within anterior portion of the eye, is thought to contribute to the intraocular pressure. 
However, this regulation of flow in relation to glaucoma is poorly understood (3). Most 
individuals suffer from sporadic glaucoma but others inherit the disease, the most 
common inherited form being primary open-angle glaucoma (POAG). Through genetic-
linkage studies performed in the past several years, three disease-causing genes have 
been correlated with POAG, the myocilin gene being the most common (1).  
Myocilin (gi accession: 4557779, geneID 4653) is found in the trabecular 
meshwork (TEM) of the eye, among other places both inside and outside of the eye. As a 
secreted glycoprotein, myocilin is thought to contribute structurally to the TEM and 
minimize the movement of the human trabecular meshwork (HTM) cells (3, 4). Myocilin 
has several distinct features: a signal sequence (Figure 1A, red), a linker with a proposed 
N-glycosylation site, a coiled-coil leucine zipper (Figure 1A, green), and an olfactomedin 
(OLF) domain (~30 kDa) (Figure 1A, yellow). The leucine zipper has been shown to 
interact with other known extracellular matrix proteins and has been proposed to be the 
site for dimerization (5-7). The OLF domain has been shown to be involved in adhesion 
and growth of neurons in mammalian brain development (8). No structure of either the 




into its role in glaucoma, through the study of disease-causing mutants, but also present 
information about the structure of the OLF domain. 
 
 
Figure 1. Myocilin domains and sequence. (A) Feature domains of myocilin (red, signal sequence; 
green, coil-coiled leucine zipper; yellow, OLF domain). Underlined segments—peptides identified by 
mass spectrometry. (B) Sequences of studied constructs (bold, full-length; blue, OLF) 
 
 
Most of the reported disease-causing mutations occur within the OLF domain of 
myocilin, and the results from recent studies implied that these mutants take on a toxic 
gain-of-function mechanism (3). Mutant myocilin is retained in the endoplasmic 
reticulum (ER), instead of being secreted to the TEM like wild-type. Cellular studies 
have shown that at lowered temperatures, some mutants can be secreted, implying that 




(9-12). Additionally, homozygous and heterozygous myocilin knockout mice along with 
individuals with an N-terminal truncated myocilin both display no ocular abnormalities 
(13, 14), implying that mutant myocilin is the source of toxicity within the HTM cells. 
 One hypothesis to overcoming the toxic effects of mutant myocilin may be 
achieved by increasing secretion of these mutants, thus reducing cellular stress caused by 
aggregation. To achieve this, mutant myocilin must pass the ER quality control 
machinery. Any protein folded in the ER, such as myocilin, is screened by ER quality 
control before being marked for secretion (15). If any irregularity is noticed, that protein 
is retained in the ER and either an attempt is made to refold it or it is marked for 
degradation. The cellular secretion studies at lowered temperature mentioned earlier 
imply that mutant myocilin probably has a slight thermal instability in the mutated 
domain but overall has a native three-dimensional structure. This slight instability can be 
detected by the ER quality control machinery that not only looks for exposed 
hydrophobic areas but also abnormalities due to biophysical properties (15). Retention of 
mutant myocilin in the ER that has not passed ER quality control leads to aggregation, 
which causes stress on the HTM cells and eventual apoptosis (10, 12, 16-18). The death 
of the HTM cells has been suggested to compromise the integrity of TEM, which can no 
longer regulate the aqueous humor. With the lack of regulation, the pressure increases, 
causing retina degradation, a key symptom of glaucoma. Therefore, glaucoma is not 
directly caused by mutations in myocilin but rather a collection of issues initiated by 
these mutations. 
 If mutant myocilin could pass ER quality control, it would be secreted as normal. 




avenue in general for protein-misfolding illnesses (19). Secreting the mutant protein from 
the ER is thought to decrease the toxicity along with the stress level of the cell (20) . 
After secretion, the cell would not be in danger of apoptosis. However, without 
knowledge of the structure, a top-down approach is needed to identify ligands or small 
molecules that could stabilize the folding of mutant protein. 
 In this thesis, the expression and purification of myocilin is described, resolving a 
previous limitation in the literature. This issue was solved by creating a fusion protein 
with maltose binding protein (MBP). A truncated myocilin, containing the OLF domain, 
and full-length myocilin were both expressed and purified (Figure 1B). In addition, 24 
mutants (both disease-causing and benign) were also expressed and purified. An assay 
was developed to study the thermal stability of both the wild-type and mutant OLF 
constructs. General trends are presented based not only on the experimentally determined 
melting temperatures of the proteins but also with data from other published studies, 
including solubility, secretion and symptomatic information of afflicted individuals. 
Additionally, several small molecules were shown to increase the stability of both the 
wild-type and mutant myocilins, which could be used in future studies to create a 
screening method for ligands. Finally, additional biophysical characterization techniques 
are detailed, giving further insight into myocilin. 
Expression and Purification of Wild-type MBP-OLF 
 Initially, a truncated myocilin composed of only the OLF domain was expressed 
first since 90% of reported disease-causing mutations are found in this region (3). 
Previous studies reported issues with expression and purification due to low yields and 




0.1 mg/mL were used in experiments and any higher concentration led to aggregation (7). 
Additionally, myocilin aggregates have been reported in cellular studies and in 
overexpression of wild-type myocilin in D. melanogaster eyes (16, 18). To overcome the 
issues of low yield and insolubility, a fusion protein was created with a N-terminal MBP, 
which has been shown in previous studies to assist in proper folding of recombinant 
proteins in E. coli (25). The protein yield was high (~2 mg/L) and the purity was 
homogeneous; thus, the protein was concentrated to ~10 mg/mL or higher. MBP and the 
OLF domain were connected by an eight amino acid linker, which was chosen over 
longer linkers to avoid elution with GroEL, an E. coli folding chaperone. This linker 
contains a Factor Xa cleavage site, a commercially available protease, to allow for 
separation of MBP and OLF. Expression trials were performed with various broths and 
different growth temperatures after induction and it was determined that Superior broth 
media and growth at 18°C overnight provided the best expression (26). Overall, the 
combination of these factors along with the use of a specialized E. coli strain contributed 
to an increased expression of MBP-OLF. 
 In the purification of wild-type MBP-OLF, a two column procedure was designed 
to isolate the monomeric fusion protein. First the wild-type MBP-OLF was purified by 
amylose-affinity chromatography, resulting in a mixture of MBP-OLF (aggregated and 
monomeric) and excess MBP, a result of cellular proteases. These fractions were then 
passed over a size-exclusion, or gel filtration, column to isolate monomeric MBP-OLF. 
The gel filtration purification yielded three distinct peaks (Figure 2B). The first peak 
corresponds to the material in the void volume, those proteins above the size cutoff to be 




aggregates. The next peak is monomeric MBP-OLF (~72 kDa) and the final peak is 
excess MBP (~42 kDa) (Figure 2B) (26). Aggregation, as mentioned earlier, has been 
observed in cellular studies (16, 27) but the relationship between these two sets of 
aggregates is unclear. However, insight can be gathered from the predicted amyloid 
regions (28) and the high β-sheet content observed in the OLF domain (21). 
To isolate monomeric OLF from MBP, cleavage of the monomeric MBP-OLF by 
Factor Xa was performed at 37 °C (26). Figure 2A shows purified wild-type MBP-OLF 
on the left (Lane 2) and purified cleaved OLF (~31 kDa) on the right (Lane 2), which was 
purified in the same manner as uncleaved after the cleavage reaction. Each gel has 







Figure 2. OLF Purification. (A) SDS-PAGE analysis of wild-type MBP-OLF (left) and cleaved OLF 
(right). (B) Sample gel-filtration chromatograph of wild-type MBP-OLF. (C) SDS-PAGE analysis of 
MBP-OLF mutants. (left gel) Lane 2—D380A; Lane 3—I477S; Lane 4—I477N; Lane 5—K423E. 
(right gel) Lane 2—wild-type; Lane 3—A427T; Lane 4—C433R; Lane 5—I499F; Lane 6—T377M; 
Lane 7—V426F. (D) SDS-PAGE analysis of MBP-SNPs. Lane 2—E352Q; Lane 3—E396D; Lane 4—






Expression and Purification of Mutant MBP-OLFs 
 Initially, four mutants (D380A, I477S, I477N, and K423E) were chosen because 
they represented a varying severity of disease-causing mutations. D380A is considered a 
mild mutant, I477S is moderate and K423E and I477N are both severe. These 
classifications are based on age of onset and intraocular pressure of the affected 
individual (12). Twenty more mutants were added to the study in order to look for overall 
trends and make general conclusions about disease-causing mutations and their role in 
glaucoma (see Table 2 for full list of mutants). 
 The expression and purification of the mutant MBP-OLFs followed the same 
procedure described above for wild-type MBP-OLF. The gel filtration column gave the 
same three distinct peaks as wild-type OLF (26). However, depending on the mutant, the 
size of the aggregation peak varied (Figure 11B-C), implying various propensities of 
aggregation, discussed further in Chapter 3. Figure 2C shows SDS-PAGE analysis of 
purified mutant MBP-OLF. The left gel displays the initial four mutants (Lane 2—
D380A, Lane 3—I477S, Lane 4—I477N, and Lane 5—K423E). On the right, the gel 
contains a selection of the twenty additional mutants (Lane 2—Wild-type, Lane 3—
A427T, Lane 4—C433R, Lane 5—I499F, Lane 6—T377M, and Lane 7—V426F). Each 
gel has molecular mass standards in Lane 1 (Figure 2C).  
 In addition to disease-causing mutations, three mutants resulting from single-
nucleotide polymorphisms (herein referred to as SNPs) were expressed and purified. 
SNPs are mutations that occur in more than one percent of the population, creating 




(rs56314834) were chosen from the Database of Single Nucleotide Polymorphisms for 
this study since they were the only missense mutations at the time of study (30). These 
SNPs were expressed and purified in the same manner as the disease-causing mutants and 
were selected to serve as a control, as they are considered benign mutations. They 
displayed similar peaks on the gel filtration chromatograph as wild-type and mutant 
MBP-OLF but the aggregation peak was smaller than the monomer peak, which was the 
opposite of the other chromatographs (Figure 11A). This difference suggests that these 
SNPs have a lower propensity for aggregation, which is discussed further in Chapter 3. 
Finally, Figure 2d shows SDS-PAGE analysis of the three SNPs (Lane 2—E352Q, Lane 
3-E396D, and Lane 4—K398R). Lane 1 has the molecular mass standards (Figure 2D). 
 Three of the mutant MBP-OLFs (A427T, G246R, and A445V) along with the 
three SNPs were cleaved with Factor Xa. Their melting temperatures are close to or above 
wild-type MBP-OLF so the cleavage reaction at 37 °C is possible. The other mutants, as 
described in Chapter 2, have melting temperatures at about 37 °C and therefore, could not 
be cleaved in this manner. Further optimization with Factor Xa could allow for cleavage 
of the mutants but for this thesis, only these six mutants were cleaved for circular 
dichroism studies. 
Expression and Purification of Full-Length Myocilin 
 With the truncated OLF domain, only part of myocilin can be studied, which is 
appropriate for the investigation of mutations and their role in glaucoma. However, for 
characterizing myocilin, a full-length protein would be needed. The full-length myocilin 
gene was first subcloned into the pET32 vector, which creates a gene encoding a Trx-
Tag™
 




nickel affinity chromatography. However, the yields were moderate, nothing compared to 
amylose affinity chromatography used with MBP-OLF. Therefore, the full-length gene 
was subcloned into the pMAL vector, creating a fusion protein with MBP. Figure 3B 
shows SDS-PAGE analysis of amylose-purified full MBP-myocilin (Lane 2). There are 
three prominent bands in Lane 2. One band around ~97 kDa corresponds to the fusion 
protein and another one at ~57 kDa is cleaved full myocilin, most likely by cellular 
proteases. The final band is about ~42 kDa, which represents excess MBP.  
 
 
Figure 3. Purification of Full Length Myocilin. (A) Heparin chromatograph. (B) SDS-PAGE analysis 
of purified full MBP-myocilin. Three bands in Lane 2: Full MBP-myocilin (~96 kDa), cleaved Full 
(~57 kDa), and excess MBP (~42kDa). Lane 1 has molecular mass standards. (C) Sephacryl S-300 
chromatograph (arrows indicate peaks). 
 
 
This full length fusion protein was expressed in the same manner as wild-type 
MBP-OLF but different purification methods were applied after isolation of the protein 
from amylose affinity chromatography. First, the sample was passed over a heparin 




sulfated polysaccharide that is a major anticoagulant and interacts with many proteins, 
mostly α-helical in nature. However, the nature of these interactions is not well 
understood (31). Myocilin may bind the heparin column through the coil-coiled leucine 
zipper, which is α-helical. The protein was eluted at ~35% Buffer B (10 mM Sodium 
Phosphate, 2 M NaCl, pH 7) shown in Figure 3A.  
An additional chromatographic method used with full MBP-myocilin was a gel 
filtration column with a high molecular weight cutoff, Sephacryl S-300. Four distinct 
peaks eluded from the column (arrows, Figure 3C). The first is the void volume, which 
contains the aggregated full MBP-myocilin, while the second peak is monomeric full 
myocilin-OLF (~96 kDa). The third peak represents cleaved myocilin (~54 kDa), most 
likely resulting from proteases, and finally, the fourth peak is excess MBP (~42 kDa).  
To confirm the identity of the purified protein, a trypsin digest was done on 
samples from the heparin and S-300 purifications. Trypsin is a serine protease that 
cleaves at a specific protein sequence (after an arginine or lysine residue). Trypsin digest 
is used to identify proteins because trypsin cleaves a protein into multiple smaller 
peptides that can be detected by mass spectrometry. The peptides are separated based on 
size by the mass spectrometer and their resulting masses are run through a database, 
which will identify the protein based on the peptides as the cleavage products (32). Table 
1 lists the peptides generated from the heparin column sample. The underlined segments 
in Figure 1A are the sequences that were identified via trypsin digest, confirming that 
full-length myocilin was eluted from the heparin resin. The protein that eluded from the 





Table 1. Identified peptides via mass spectrometry from full-length myocilin. 
 
 
Expression and isolation of monomeric wild-type MBP-OLF and mutants allowed 
for characterization of these proteins. The thermal stability of each was determined, 
described in Chapter 2, and additional biophysical techniques were performed to gather 
further information about myocilin, discussed in Chapter 3. However, for full-length 
myocilin, the expression and purification is the only work included in this thesis. Now 
with established expression, further optimization with purification of full-length myocilin 
will allow for future research in the characterization of this protein. 
  
Residue Range Sequence Calculated Mass (Da) Observed Mass (Da)
148-156 DKSVLEEEK 1076.547 1076.5576
159-168 LRQENENLAR 1242.6549 1242.6864
169-179 RLESSSQEVAR 1261.6495 1261.6813
127-136 ERDQLETQTR 1275.6288 1275.6675
137-147 ELETAYSNLLR 1308.6794 1308.7184





DEVELOPMENT OF A QUNTITATIVE ASSAY 
 A novel thermal stability assay was developed to compare wild-type and mutant 
MBP-OLF. This assay was adapted from a previously published fluorescence assay, 
designed to study the stability of proteins in the presence of buffers, salts and other small 
molecules (33). In this experiment, a real-time (RT)-PCR was used since it can detect the 
emission of SYPRO orange, a dye known to bind to the hydrophobic portion of a protein. 
As the protein unfolds due to the increase in heat, the signal of SYPRO orange also 
increases due to the binding onto exposed hydrophobic areas of the protein (33). The 
melting temperature (Tm), the point at which half of the protein is folded and half is 
unfolded, can be determined from the melting curve. It is the midpoint of the curve, 
assuming a two-state transition. The higher the Tm, the more stable the protein. Trends 
can be deduced from the melting temperatures of the protein alone and in the presence of 
osmolytes. 
Since MBP-OLF is a fusion protein, control experiments were performed to 
determine if the melting curves of OLF-MBP could be distinguished from one another. 
First, the melting temperature of MBP was studied with and without maltose. Previous 
studies have shown that the binding of a ligand increases the stability of a protein (34); 
the binding of maltose, the ligand for MBP, should raise the Tm of MBP to be higher than 
OLF’s. The melting temperature of MBP without maltose was 56.1 °C but in the 
presence of maltose the Tm shifted to 67.1 °C (Figure 4A) (26). The melting temperature 
was increased by 11 °C, significant enough to separate from the melting of OLF. 




of cleaved OLF with and without maltose and MBP-OLF with maltose. The three curves 
overlay exactly showing that maltose has no effect on the melting temperature of OLF. 
Finally, MBP-OLF’s melting temperature was determined with and without maltose. 
Without maltose, the Tm of the fusion protein was 51.8 °C but with maltose, two 
discernable transitions are seen (Figure 4C). The melting temperature of the first peak is 
52.7 °C and the second is ~67 °C. The first curve is shown trimmed in Figure 4B, which 
overlays with the melting curves of cleaved OLF, indicating that the first transition is the 
melt of OLF. The second temperature of 67 °C is close to the melting temperature of 
MBP in the presence of maltose (67.1 °C). The second transition can be concluded to be 
the melting of MBP. Overall, the melting of OLF can be distinguished from the melting 






Figure 4. Melting Curves. (A) Cleaved OLF with and without maltose. (B) Cleaved OLF with and 





After the Tm of wild-type MBP-OLF was determined, the Tm of the 21 disease-
causing mutants and three SNPs were determined. Figure 5 shows the melting curves for 
all 24 proteins, grouped together with different colors. The mutants (K423E, I477N, and 
Y437H) with the lowest melting temperature are shown in red. C433R and I499F, in 
black, are group together due to their broad melting curve. Next the mutants with a 
medium melting temperature are split into blue (lower melting temperature) and light-
blue (higher melting temperature). With the inclusion of wild-type in grey, the green 
melting curves describe the mutant proteins (A427T, G246R, G326R, and A445V) with 
the highest melting temperatures. Finally, the SNPs (K398R, E396D, and E352Q) are 
also colored in gray and show a Tm higher than wild-type MBP-OLF. Almost all of the 
mutants and wild-type show a sharp sigmoidal transition, indicative of a two-state 
unfolding. However, C433R and I499F have broad transitions, implying unfolding 





Figure 5. Melting Curves of Wild-type and Mutants. 
 
 
The diseasing-causing mutants are generally less stable than wild-type MBP-OLF, 
signified by their lower melting temperatures. However, four mutants (A427T, G246R, 
G326R, and A445V) have Tm’s near or above that of wild-type, suggesting that these 
mutations might not be disease-causing mutants or if they are, very mild disease-causing 
mutants. Additionally, the SNPs have melting temperatures above wild-type and are 
known to be benign mutations. Therefore, these four mutants are likely benign mutations 
instead of disease-causing mutations due to their high melting-temperature. 
 If the stability could be increased enough to pass ER quality control, then the 
mutant protein could be secreted into the trabecular meshwork, maintaining its integrity. 
A small molecule binding to or affecting the folding of mutant myocilin would be ideal to 




chemical, or pharmacological, chaperones when they are targeted for specific binding. 
Pharmacological chaperones have been studied numerous times for therapeutic use to 
increase thermodynamic stability of proteins (19, 35-38). Drawing from these examples, 
wild-type and mutant myocilins were tested with seven common osmolytes, a subset of 
chemical chaperones, as a proof-of-concept that these mutants could be stabilized. These 
osmolytes are small molecules that maintain protein homeostasis in eukaryotic cells 
exposed to osmotic stress (39). Osmolytes destabilize the unfolded state of the protein, 
pushing the equilibrium towards the folded state by creating an environment unsuitable 
for the protein backbone (40-43). This shift in equilibrium towards the folded state 











First, the effects of betaine, glycerol, proline, sarcosine, sucrose, trimethylamine 
N-oxide (TMAO), and 4-phenylbutyrate (4-PBA) (structures shown in Figure 6) were 
tested on cleaved OLF and MBP-OLF. The wild-type protein was examined first. If the 
wild-type mutant is stabilized by these osmolytes then the mutants should be as well. To 
determine if the effect of the osmolytes on the OLF domain of the fusion protein could be 
discerned, both cleaved OLF and MBP-OLF were tested. Figure 7A shows the melting 
curves of MBP-OLF protein in buffer along with the melting curves in the presence of 
osmolytes. All of the osmolytes, except 4-PBA, increased the melting temperature in the 
following order: sacrosine, TMAO, sucrose (~8-10 °C), proline, betaine, glycerol (~2-4 
°C) (Figure 7A, Table 2) (26). The difference between the melting temperature of cleaved 
OLF and MBP-OLF was approximately 0.3 °C so the effect on the OLF domain could be 
distinguished. Therefore, only the melting temperatures for MBP-OLF are reported. 
Since 4-PBA had no effect on MBP-OLF, its melting curve is not displayed in Figure 7A 





Figure 7. Melting curves of select MBP-OLF proteins in presence of osmolytes. (A) Wild-type MBP-





Figure 7 shows the melting curves of the initial four disease-causing mutants. Out 
of the seven osmolytes, sarcosine and TMAO had the greatest effect on these mutants, 
bringing the melting temperature close to or above the Tm of wild-type MBP-OLF in 
buffer. This trend continues for all of the remaining disease-causing mutants and three 
SNPs with an increase of Tm of seven degrees or higher for both sarcosine and TMAO 
(Table 2). Furthermore, Table 2 reports all of the melting temperatures in the presence of 
each osmolyte for all disease-causing mutants and SNPs, except for E323K and V426F. 
The melting temperatures of these two mutants in buffer and in TMAO were the only 
Tm’s reported because the yield of MBP-OLF monomer from these mutants was very 
low. In addition to sarcosine and TMAO, sucrose increased the melting temperature but 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Combining previously published data and the melting temperatures reported, the 
mutants can be sorted and conclusions can be made based on this order as to their role in 
glaucoma. Table 3 shows the 20 disease-causing mutants, three SNPs and wild-type 
MBP-OLF ranked by the melting temperature in buffer only. Based on these melting 
temperatures and those in the presence of TMAO, the mutants can be categorized into 
four groups. Group 1 includes P380L and W286R with no melting temperature reported 
due to low monomeric yield because of a high propensity for aggregation. Next, Group 2 
represents the mutants with the lowest melting temperature (I477N, K423E, and Y437H). 
Furthermore, these mutants were not stabilized by TMAO to wild-type’s Tm unlike Group 
3. Group 3 includes the mutants with mid-range Tm’s, representing the largest group. 
Finally, the Group 4 includes the three SNPs and three disease-causing mutants (A427T, 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Three other sources of data were included in Table 3 from which inferences can 
be made when combined with the melting temperatures. The results from a solubility 
assay are reported for most mutants; in Table 3, NA stands for not applicable for those 
mutants not included in these experiments. In this assay, the solubility of each protein in 
the presence of a detergent, Triton-X 100, was investigated. Those proteins found in the 
soluble portion were deemed as benign mutations while any mutant in the insoluble 
fraction was considered disease-causing (44, 45). In Table 3, I represents insoluble, PI 
means partially insoluble, and S stands for soluble in the “Solubility Assay” column. 
Referring back to the four groups above, the proteins of Groups 1 and 2 are completely 
insoluble while Group 3 proteins are a mix of insoluble and partially insoluble. In Group 
4, all proteins are soluble except for one, G246R (Table 3). Generally, most of the 
proteins are insoluble, which according to the guidelines set forth by Zhou et al, makes 
all of these disease-causing mutants. However, Group 4 would be considered benign 
mutations since most of them are soluble, suggesting that the reported disease-causing 
mutants in this group might have been mislabeled or just very mild mutants. 
 The secretion of each mutant from cells at two different temperatures is shown in 
Table 3. These cells were grown initially at 37 °C and the amount of protein secreted was 
determined qualitatively through immunobloting. Some of the mutants showed secretion 
at 37 °C but the temperature was lowered to 30 °C to see if the other mutants might be 
secreted (9, 12). In Table 3, in the “Secretion Assay” column, N stands for no secretion, 
+/- means little secretion and +, ++, and +++ represents increasing secretion, according to 
Gobeil et al (9). Groups 1 and 2 proteins show no secretion at 37 °C and partial secretion 




almost all of the mutants are secreted. Finally, proteins in Group 4 are secreted at 37 °C, 
rendering the experiment at 30 °C unnecessary. Similar to the trend of the solubility 
assay, the first three groups have little secretion at 37 °C while the fourth group has 
normal secretion, providing more evidence for these mutations being benign. However, at 
30 °C, there is a trend among the first three groups. Groups 1 and 2 did not secrete or had 
little secretion even at 30 °C, implying that the mutations are very unstable. Conversely, 
Group 3 had secretion at 30 °C, showing that the mutants are only moderately unstable. 
The lower temperature is further away from the Tm so the probability of the protein being 
folded is higher. Also at the lower temperature, the mechanisms in the cell are slower so 
the protein has a better chance of folding correctly.  
 Finally, the age of diagnosis of glaucoma is reported for each mutant in Table 3 
when available. These data were collected through genetic studies looking at either 
families or populations for individuals with glaucoma. Once an individual was identified, 
their myocilin gene was sequence and if any mutation was found, it was reported as a 
disease-causing mutation. Mutations identified in families and populations often 
overlapped and were published in multiple studies (46-60). A correlation was expected to 
arise between the age of diagnosis and the order of the severity of the mutants. However, 
although each study uses similar methods of diagnosis, no clear guidelines were 
established when defining age of diagnosis. Since the ages reported are only for 
diagnosis, the actually age of onset is unknown and therefore, a correlation cannot be 
made between the ranking of severity of the mutants and the reported ages.  
However, conclusions can be made if all of the data presented in Table 3 is 




secreted; therefore, they can be considered severe mutations. Generally, the individuals 
with these mutations are younger when they are diagnosed with glaucoma (Table 3). 
Proteins in Group 3 were insoluble to partially insoluble and efficiently secreted at 30 °C, 
suggesting that they are moderate mutations. Here the age of diagnosis data is varied 
greatly, so no correlation can be made but the mutants can still be considered moderate 
based on the other data. Finally, the mutants in Group 4 could have easily been 
mislabeled as disease-causing mutations. Those individuals with the A427T or A445V 
mutation, who were aged 63 and 73 at diagnosis respectively (Table 3), could have 
developed glaucoma from another source than these mutations (50). Therefore, these 
mutations could be considered benign or very mild mutations, further supported by the 







 In studying the structure of wild-type myocilin, circular dichroism (CD) was used 
to discern information about its secondary structure in comparison to the mutant 
myocilins. Additionally, thioflavin T, a fluorescent dye, was used to determine the nature 
of the aggregates observed during gel-filtration purification. Using these biophysical 
techniques and comparing the propensity for aggregation of wild-type and mutants, new 
insight on myocilin’s structure could be inferred and possibly offer implications for its 
role in glaucoma. 
Circular Dichroism 
Circular dichroism is a technique used in biochemistry to study the secondary 
structure of proteins. Circularly polarized light travels through a sample interacting with 
any chiral molecules. A spectrum is produced from these interactions and certain spectral 
fingerprints are used to assign secondary structure to the protein (61). For example, an α-
helix has negative minima at 208 and 222 nm and a positive maximum at 190 nm, while a 
β-sheet has a minimum at 215 nm and a maximum at 198 nm (62). Figure 8 shows the 
CD spectra of wild-type MBP-OLF along with four mutants (D380A, I477N, I477S, and 
K423E) (26). In each spectrum, minima are observed at 208 and 222 nm, representing α-
helical content. These minima come from MBP, which is primarily α-helical. Another 
minimum is observed around 217 nm, which is characteristic of a β-sheet. Myocilin is 
comprised of β-sheets however the α-helical signal from MBP overwhelms most of the 
signal from β-sheets, making it difficult to distinguish the contribution of myocilin to the 




the spectra of cleaved proteins. In these spectra, the minima at 208 and 222 nm are not 
observed and the β-sheet characteristic of myocilin is very prominent with the minimum 
at 217 nm. Also the spectra for the SNPs (E352Q, E396D, and K398R) overlay with 
wild-type OLF along with those of the mutants (A427T, G246R, and A445V). This 
overlap provides more evidence that there are no gross structural differences between the 






Figure 8. Characterization of MBP-OLF and mutants by CD. 
 





Thioflavin T Assay 
 As mentioned previously, during gel filtration purification, aggregates of myocilin 
are observed in the void volume. One form that these aggregates can take is amyloid 
fibrils. One way to characterize a protein as a fibril is 
with the use of the fluorescent dye Thioflavin T (Figure 
10). The fluorescence of thioflavin T (ThT) increases 
upon binding to amyloid fibrils. In the structure of 
ThT, the dimethylamino group on the right side of 
the molecule is hydrophobic while the benzothiazole group on the left is hydrophilic. 
This arrangement of hydrophilic and hydrophobic regions in the dye is believed to be the 
reason thioflavin T binds to amyloids (63). Binding to the fibril fixes ThT into place, 
creating an increase in fluorescence. Table 4 shows the intensity of protein aggregates in 
the presence of Thioflavin T. Any appreciable intensity signifies the presence of 
amyloids, as the monomer protein gives no fluorescence signal. Interestingly, not only 
did the disease-causing mutants MBP-OLF display evidence of amyloids but also the 
SNPs, wild-type MBP-OLF, and full-length myocilin. 
  





































Propensity of Aggregation in Size-exclusion Chromatography 
 Gel filtration chromatography is an effective way to separate aggregated protein 
from monomeric protein (64). For all OLF variants studied, aggregation was observed in 
the void volume from gel filtration. The ratio between the aggregate and monomer peak 
of a given protein can give information about the propensity to aggregate when compared 
to other proteins. For example, in Figure 11A, wild-type MBP-OLF has a 6:4 aggregate 
to monomer peak ratio. However when compared to E396D, overlaid in red, wild-type 
has higher aggregation than the SNPs because E396D has an 8:2 monomer to aggregate 
ratio. The SNPs’ chromatographs gave an interesting observation, implying that SNPs 
have a low propensity for aggregation. On the other hand, mutant MBP-OLFs gave a 
variety of different ratios, which can be loosely linked to the ranking of mutants in Table 
3. For instance, Figure 11B shows wild-type MBP-OLF and G367R. G367R gives about 
a 9:1 aggregate to monomer peak and there is a high level of aggregation. When 
compared to wild-type, the ratio of monomer to aggregate for G367R implies a decent 
propensity for aggregation. However, when looking at Figure 11C, W286R gives no 
monomeric peak, signifying almost complete aggregation. Table 3 shows that W286R 
has no melting temperature, due to this issue of complete aggregation, while G367R has a 
medium melting temperature. Based on this information, W286R could be considered 
more of a severe mutation than G367R. This conclusion can give more evidence to the 




 Overall, the data present in this thesis give insight into the relationship between 
the genotype and phenotype of POAG. The severity of the mutation can be deduced by 
the melting temperature, aggregation propensity, and additional data presented in Table 3. 
Groups 1 and 2 would be severe while Group 3 mutants could be moderate. Finally, 
Group 4 mutations are either very mild or benign. Furthermore, the thermal stability 
assay demonstrated these mutants can be stabilized by small molecules. This assay is the 
beginning step in designing a high-throughput assay to identify small molecule stabilizers 
for myocilin. Future research can refine this assay to identify a small molecule, which can 








Figure 11. Size exclusion chromatography. (A) Wild-type MBP-OLF and E396D. (B) Wild-type 
MBP-OLF and G367R. (C) Wild-type MBP-OLF and W286R. Blue line represents wild-type and red 






MATERIALS AND METHODS 
Molecular Biology.  The MYOC-OLF gene was amplified by polymerase chain 
reaction (5-PRIME Master Mix, Fisher Scientific) from a plasmid reported previously 
(45), annealed into the pET-30 Xa/LIC vector (Novagen), then subcloned into the pMAL-
c4x vector (New England Biolabs). The final pMAL-c4x construct incorporates a 7-
amino acid linker between MBP and OLF (SSSIEGR), with a Factor Xa cleavage site 
(IEGR). After plasmid replication in NovaBlue Gigasingles (Novagen), the plasmid was 
isolated (QIAPrep, Qiagen). Mutant MBP-OLFs were generated by site directed 
mutagenesis (QuikChange, Stratagene). Primers used for mutagenesis are listed in 
Appendix 1. All plasmids were verified by DNA sequencing (Operon). 
Protein Expression and Purification.  Wild type and mutant plasmids were 
transformed into Rosetta-gami 2(DE3)pLysS (Novagen) cells and cultured in Superior 
Broth (US Biological) to an optical density of ~0.7 at 600 nm, cooled to 18 °C, and 
induced with 0.5 mM isopropyl -D-thiogalactopyranoside. After overnight growth (12–
16 hours), cells were pelleted, flash frozen, and stored at –80 °C. 
Cell pellets were lysed by French Press in the presence of 10 mM 
sodium/potassium phosphate (pH 7.2), 200 mM NaCl, 1 mM EDTA (Buffer A), 
supplemented with Roche Complete Protease Inhibitor. Cell debris was removed by 
ultracentrifugation (42000 g for 30 min) and the clarified supernatant loaded onto a 20 ml 
High Flow Amylose Resin (New England Biolabs) column equilibrated with Buffer A. 
The MBP-OLFs were eluted with Buffer A plus 10 mM maltose, concentrated using an 




or loaded on a Superdex 75 gel filtration prep grade column (GE Healthcare) equilibrated 
with 10 mM Phosphate (Na/K), 200 mM NaCl, pH 7.2 (Buffer B). Only those fractions 
corresponding to monomeric MBP-OLF were pooled for further study.  
Cleavage of MBP-OLF was accomplished by overnight (~ 16 h) incubation with 
Factor Xa (New England Biolabs) in 50 mM Tris pH 8, 100 mM NaCl, 5 mM CaCl2. 
Cleaved OLF was fractionated from uncleaved material and MBP by taking the 
flowthrough fraction from amylose resin for purification on Superdex 75. MBP used in 
these studies was also isolated this way. Protein in experiments was used within three 
days of purification. SDS-PAGE analysis was conducted as described (65). 
Thermal Stability Assay.  Sypro Orange (Invitrogen), supplied as a 5,000X 
solution in dimethylsulfoxide, was diluted in Buffer B (1:1000) and mixed just prior to 
preparing samples for the assay. Reactions of 30 L were prepared at room temperature 
and delivered to 96-well optical plates (Applied Biosystems) before sealing with optical 
film. 3 L of diluted Sypro Orange was added to the protein solutions ranging in 
concentration from 0.5–1.5 M. Protein samples were in Buffer B. Except when 
indicated otherwise, maltose was present at 50 mM. Compounds tested for stability 
enhancement were obtained from commercial sources. Where indicated, TMAO and 
sarcosine were tested at 5 M in the reaction buffer, whereas 4-PBA was tested in a 
concentration range of 1 mM to 0.5 M. For all others, a 5 M stock was diluted to 3 M in 
Buffer B. Plates included a baseline control containing Sypro Orange with no protein. 
The pH of the final solutions did not deviate significantly from 7. 
Fluorescence data were acquired on an Applied Biosciences Step-One Plus RT-




emission filter (610 nm). Melting experiments were conducted from 25–95 °C with a 1 
°C per min increase. No difference in Tm was observed when the rate of heating was 
slowed to 0.5 °C per min. No dependence of protein concentration on Tm was observed 
above a minimum threshold protein concentration. Data were processed using GraphPad 
Prism. After baseline subtraction, data were trimmed to include the boundaries and the 
transition of interest and normalized. The reported Tm is the inflection point of the 
sigmoidal curve, which was fit as described previously (33). 
Circular Dichroism.  Prior to CD scans, monomeric MBP-OLF samples were 
purified once more on an analytical Superdex 75 GL column (GE Healthcare) to remove 
all traces of aggregate or MBP and then concentrated to 0.25-0.5 μM (uncleaved protein) 
or 1.0-5.0 μM (cleaved protein). CD spectra were acquired at 25 °C on a Jasco J-810 CD 
spectropolarimeter. Twenty consecutive scans (forty for cleaved protein) ranging from 
200 nm to 300 nm, using a bandwidth of 1 nm at a continuous scanning rate of 500 
nm/min, were averaged for each sample. 
Thioflavin T. The presence of amyloid fibrils was determined using a 
fluorescence dye thioflavin T. A stock solution of thioflavin T was prepared by dilution 
in deionized water to 1 mg/mL. Thioflavin T was further diluted to 5 μM in Buffer A 
with 0.25 mg/mL aggregate protein (taken from void volume of gel filtration 
purification). Fluorescence emission spectra of thioflavin T-protein complex were 
recorded using excitation and emission wavelengths of 412 and 430-600 nm respectively, 
using a Shimadzu RF-5301 PC spectrofluorophotometer. The average of three intensities 




 In-gel trypsin digest and mass spectroscopy (MALDI-TOF/MS) analysis. 
Full-length myocilin was excised from a SDS-PAGE and acetonitrile was added to 
dehydrate the gel pieces. Ten mM dithiotreitol (DTT) in 100 mM ammonium bicarbonate 
was added after removal of the acetonitrile. The solution was incubated for an hour at 56 
°C and then with the removal of the DTT solution, 55 mM iodoacetamide in 100 mM 
ammonium bicarbonate was added. Incubated for 45 minutes in the dark, the gel pieces 
were vortexed every 15 minutes. The iodoacetamide solution was replaced with 100 mM 
ammonium bicarbonate and then with acetonitrile to dehydrate the gel pieces. This 
process was repeated three times. After the final dehydration, the gel pieces were dried 
with a speed-vac and rehydrated with the digestion buffer (50 mM ammonium 
bicarbonate, 5 mM calcium chloride, and 12.5 ng/μL trypsin (Promega, mass 
spectrometry grade)). After incubation in an ice bath for 45 minutes, this solution was 
replaced with digestion buffer without trypsin and incubated overnight at 37 °C. Twenty 
mM ammonium bicarbonate followed by three cycles of 5% formic acid in 50% 
acetonitrile was performed to extract the digested peptides from the gel pieces (66). The 
combined extractions were dried in a speed-vac and submitted to the Georgia Institute of 
Technology Bioanalytical Mass Spectrometry Facility for peptide mass fingerprinting 
analysis. Spectra were acquired on a MALDI-TOF/TOF tandem mass spectrometer, 
Applied Biosystems 4700 Proteomics Analyzer. All peaks were deisotoped and analyzed 
by GPS Explorer (Applied Biosystems) software, specifically the MASCOT program. 
The National Center for Biotechnology non-redundant (NCBInr) database was searched 
with the following  parameters: homo sapiens as taxonomy; trypsin as the enzyme; up to 



















 Primer Used 













  Reverse 5’-GCCGAATTCAGGAGAGTTAGAGCCTTATCA 






  Reverse 5’-GCCGAATTCTTATCACATCTTGGAGAGCTTGAT 
   Mutagenesis 
D380A   5’-GCTACACGGACATTGCCTTGGCTGTGGATG 
I477S   5’-GTACAGCAGCATGTCTGACTACAACCCCCTCG 
I477N   5’-GTACAGCAGCATGAATGACTACAACCCCCTGG 
K423E   5’-GGGAGACAAACATCCGTGAACAGTCAGTCGCCAATGCC 
T377M   5'-GTATTCTTGGGGTGGCTACATGGACATTGACTTGGCTGTG 
A427T   5'-CATCCGTAAGCAGTCAGTCACCAATGCCTTCATCATCTG 
C433R   5'-CAATGCCTTCATCATCCGTGGCACCTTGTACACC 
I499F   5'-GAACATGGTCACTTATGACTTCAAGCTTTCCAAGATGTG 
Y437H   5'-CATCTGTGGCACCTTGCACACCGTCAGCAGCTAC 
P481L   5'-GCATGATTGACTACAACCTGCTGGAGAAGAAGCTCTTTG 
R272G   5'-CAAGTATGGTGTGTGGATGGGAGACCCCAAGCCCACCTAC 








 Primer Used 
N480L   5'-CAGCAGCATGATTGACTACCTACCCCTGGAGAAGAAGCTC 
S502P   5'-CACTTATGACATCAAGCTTCCCAAGATGTGATAAGGCTC 
G364V   5'-GAAATCCCTGGAGCTGTCTACCACGGACAGTTC 
G367R   5'-GGAGCTGGCTACCACAGACAGTTCCCGTATTC 
A445V   5'-GCAGCTACACCTCAGTAGATGCTACCGTCAAC 
E323K   5’-CATACTGCCTAGGCCACTGAAAAGCACGGGTGCTGTGG 
V426F   5'-CAAACATCCGTAAGCAGTCATTCGCCAATGCCTTCATCATC 
G252R   5'-GAACTAGTTTGGGTAAGAGAGCCTCTCACGC 
G246R   5'-GGAGACACCGGATGTAGAGAACTAGTTTGGG 
G326R   5'-CCACTGGAAAGCACGCGTGCTGTGGTGTAC 
W286R   5'-CCCAGGAGACCACGAGGAGAATCGACACAG 
K398R   5’-CGATGAGGCCAGAGGTGCCATTGTCCTCTC 
E396D   5'-CATTTACAGCACCGATGACGCCAAAGGTGCCATTGTC 
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